When a BRCA1/2 reversion mutation was identified in pretreatment samples from patients with ovarian cancer receiving rucaparib, the median progression-free survival (PFS) was noted to be shorter compared with those without reversion mutations (1.8 months versus 9 months) [14]. This evidence concerns the gene BRCA1 and ovarian cancer.